Quarterly report [Sections 13 or 15(d)]

Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details)

v3.26.3
Schedule of Reportable Segment Profit and Loss, Including Significant Expense Categories (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2026
Jun. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Jun. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Segment Reporting [Line Items]                
Total $ 183,157 $ 3,266 $ 3,377 $ 3,437 $ 3,934 $ 2,834 $ 189,800 $ 10,205
Reportable Segment, Aggregation before Other Operating Segment [Member]                
Segment Reporting [Line Items]                
Preclinical, clinical trial and other costs 1,465     1,204     3,214 4,543
Research and development personnel expense [1] 346     458     1,056 1,154
Acquired IPR&D expense 178,030         178,030
General and administrative personnel expense [2] 705     855     1,967 2,158
Administrative and facilities expense [3] 3,583     972     5,530 2,432
Other expense, net [4] (972)     (52)     3 (82)
Total $ 183,157     $ 3,437     $ 189,800 $ 10,205
[1] Research and development personnel costs include employee stock-based compensation expense of $57 and $110 for the three months ended September 30, 2026 and 2025, respectively, and $92 and $166 for the nine months ended September 30, 2026 and 2025, respectively.
[2] General and administrative personnel costs include employee stock-based compensation expense of $182 and $193 for the three months ended September 30, 2026 and 2025, respectively, and $283 and $438 for the nine months ended September 30, 2026 and 2025, respectively, and are net of reimbursements received from CorLyst, LLC.
[3] Administrative & facilities expense primarily consists of facilities expenses, office expenses, legal costs, insurance, consulting, travel, and other administrative costs.
[4] Other income, net consists of interest and dividend income, realized and unrealized losses on our digital assets, and other miscellaneous income.